Utilization of Measles-Containing Vaccines in Children Aged 12 to 47 Months from 2015 to 2025
By
Meaghan S. Fagalde
Libby C. Page
Ellyn P. Marder
M. Mia Shim
Sharon Bogan
Disha Patel
Meagan K. Kay
Eric J. Chow
July 10, 2026
Clinical Scorecard: Utilization of Measles-Containing Vaccines in Children Aged 12 to 47 Months from 2015 to 2025
At a Glance
Category Detail
Condition Measles-containing vaccines (MCV) Key Mechanisms Preventing infection and community transmission of measles and varicella. Target Population Children aged 12 to 47 months in King County, Washington. Care Setting Public health surveillance and vaccination clinics.
Key Highlights
64% of children received coadministered MMR + VAR as their first dose. 15% of children received MMRV as their first MCV and VCV dose. Significantly more MMRV-receiving children were from minoritized racial and ethnic groups. 95% of children received both MCV and VCV before age 4 years. Racial and ethnic disparities in vaccination coverage have declined since the VFC program implementation. Guideline-Based Recommendations
Diagnosis
Management
ACIP recommends coadministered MMR and VAR (MMR + VAR) as the preferred first dose for children younger than 4 years. Monitoring & Follow-up
Risks
Increased risk of febrile seizures associated with MMRV. Patient & Prescribing Data
Children aged 12 to 47 months in King County, Washington.
Combination vaccines like MMRV improve coverage by reducing the number of injections and clinic visits.
Clinical Best Practices
Ensure access to recommended vaccines for VFC-eligible children. Monitor vaccination patterns to identify populations at risk of not receiving recommended vaccines. Related Resources & Content
